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Background: While the incidence of patients with atopic dermatitis (AD) with atopic march (AM) showing
respiratory allergy is steadily rising, the pathomechanism is still unknown. There are currently no biomarkers
to predict progression of AM.
Methods: To explore the mechanism of AM, patients with AD and AM and healthy controls were recruited
and RNA microarray, flow cytometry, quantitative real-time polymerase chain reaction, and immunofluores-
cence staining were performed. We also co-cultured dendritic cells and CD4+ T cells with various Dermato-
phagoides farinae allergen fractions. Cytokine levels were evaluated using enzyme-linked immunosorbent
assay.
Findings: Both fatty-acid-binding protein 5 (FABP5) and Th17-related genes were more highly expressed in
AM. FABP5 knockdown significantly decreased Th17-inducing cytokines in keratinocytes and IL-17A in T cells
from AM patients. Further confirmation was obtained using an AM mice model compared to mice without
AM. Der f 1, a major D. farinae allergen, increased FABP5 and IL-17A expression in T cells from AM patients.
Higher serum FABP5 levels from AM patients were positively correlated with serum IL-17A levels.
Interpretation: FABP5 expression, possibly enhanced by higher epicutaneous and respiratory sensitization to
Der f 1, may directly promote Th17 responses in AD patients with AM. Thus, AM progression can be
explained by Th17 reaction induced by FABP5. FABP5 was identified as a potential biomarker in AM.
Funding: This study was supported by the National Research Foundation of Korea (NRF) grant funded by the
Korea government (Ministry of Science and ICT; No. NRF-2017R1A2B4009568), grants of the Korean Health
Technology R&D Project, Ministry for Health, Welfare & Family Affairs, and the Republic of Korea
(HI13C0010, HI14C1324, HI14C1799).
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Research in context
Evidence before this study
Past studies have shown that patients with atopic dermatitis
have the tendency of developing atopic march, the progression
of atopic dermatitis in infancy and early childhood to subse-
quent airway hyperresponsiveness such as allergic rhinitis and
asthma, in the later stages of their lives. Th 17 inflammation,
which is often observed in systemic inflammation, has been
proposed to be involved in atopic march. As yet, the mechanism
to explain how this reaction induces atopic march has not been
identified and a biomarker to predict atopic march is still
unknown.
Sources
We performed a literature search in the PubMed database using
the terms “atopic dermatitis” and “atopic march” or “allergic
march” or “systemic inflammation” and “pathogenesis”, or
“biomarker”, or “Dermatophagoides”, or “Dermatophagoides fari-
nae”, or “der f”, or “der f fraction”, or “T cell”, or “IL-17”, or
“Th17”, or “immune” and/or “response”, or “psoriasis” and/or
“lipid metabolism”, and/or “fatty acid metabolism”, and/or
“fatty acid binding protein 5”, or “epidermal fatty acid binding
protein”, or “fatty acid binding protein 4” to find evidences
before and while we are undertaking this study.
Added value of this study
A heatmap using a whole genome transcriptome displayed
increased expression of genes related with fatty acid metab-
olism in the atopic march group when compared with the
atopic dermatitis group without atopic march and with
healthy controls. Among them, fatty acid binding proteins
families, especially fatty acid binding protein 5-related
genes, were most highly expressed. Consistently, increased
fatty acid binding protein 5 expression was confirmed in
human skin samples and T cells with atopic march and
murine atopic march model’s skin, lung and T cells, in
accordance with increased IL-17A level, when compared
with atopic dermatitis samples and healthy controls. Knock-
down of fatty acid binding protein 5 in T cells inhibited IL-
17A expression. Direct correlation was observed between
fatty acid binding protein 5 expression and IL-17A level.
Overall, the results indicate that ‘fatty acid binding protein
5’ may serve as a prudent biomarker to explain the progres-
sion of atopic march in atopic dermatitis patients, acting by
directly promoting Th17 inflammation.
Implications of all the available evidence
Our findings imply the possibility to predict the atopic
march progression with an identifiable biomarker ‘fatty acid
binding protein 5’, in relation to the past findings regarding
the mechanism of inflammation transfer within the body
system by Th17 inflammation. This will help clinicians to
explain the in-depth mechanism of atopic march, predict
atopic dermatitis patients with higher risk of atopic march
progression and provide more detailed information to such
patients. Furthermore, this study will be useful for research-
ers in various departments and academia regarding the
involvement of fatty acid binding protein 5 in Th17-medi-
ated systemic inflammatory diseases.
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Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin
disease that limits the patient quality of life [1,2]. AD is also consid-
ered a systemic disease [3] that is associated with autoimmune disor-
ders [4] and involvement of the ocular [5], gastrointestinal [6,7], and
renal systems [8]. The strongest evidence for systemic involvement is
the phenomenon called “atopic march” (AM) [9].
The concept that AM represents AD as a systemic disease is sup-
ported by cross-sectional and longitudinal studies [1013]. Impor-
tantly, atopy is the familial or personal propensity to produce
systemic IgE antibodies with sensitization to inhaled and food aller-
gens [14]. Atopy links the conditions of AD, allergic rhinitis (AR), and
allergic asthma (AA) [15-17]. Classically, AD constitutes only a part of
the atopy complex, which encompasses skin changes usually com-
bined with airway involvement, including the lung and nasal mucosa,
leading to the progression from atopic eczema to respiratory allergic
diseases [15,18]. Although these conditions can develop indepen-
dently, early eczematous skin lesions and later-onset respiratory dis-
orders share a common pathogenesis [18].
While the exact pathomechanism of AM has not been identified,
several possibilities have been previously proposed. One potential
mechanism of AM pathogenesis posits that a defective skin barrier
during childhood eczema allows entry of high-molecular-weight
allergens, bacteria, and viruses, eventually causing airway hyperres-
ponsiveness (AHR) [19,20]. Importantly, AHR requires the involve-
ment of T cells [21]. Furthermore, epicutaneous entry of
environmental allergens through barrier-disrupted skin induces thy-
mic stromal lymphopoietin (TSLP) expression and is strongly associ-
ated with the induction of type 2 helper T cells (Th2). Th2 cells
further contribute to airway sensitization and inflammation [22,23].
Although most previous AM studies have focused on Th2
responses, a study showed that interleukin (IL)17A signaling might
also contribute to AM pathogenesis [24]. Specifically, allergen-
induced IL-6 trans-signaling activated gd T cells and promoted both
Th2- and Th17-mediated airway inflammation [25]. IL-6 and other
cytokines also stimulated Th17 differentiation. Taken altogether,
these data suggest that Th17 responses may contribute to AM devel-
opment even though the underlying mechanism of AM in relation-
ship with Th17 remains unclear.
The aim of this study is to elucidate the Th17-related mechanism
of AM pathogenesis and to identify a biomarker to predict the high-
risk patients for AM progression among AD patients. Therefore, in
this study, we developed AM mice models and sampled skin and
serum from healthy controls (HC), AD and AM patients to elucidate
the Th17-related mechanism. Whole genome transcriptome analysis
was done to find a target protein which promotes Th17 responses
and gene expressions were analyzed using microarray and quantita-
tive PCR. Immunofluorescence was performed to visualize the target
protein in tissue samples. A knockdown experiment was done to clar-
ify the direct relationship between our candidate protein and Th17
response. Our data confirmed the Th17-related mechanism of AM in
a relation with a protein named fatty acid binding protein 5 (FABP5),
which may be a novel biomarker to predict AM progression in AD
patients.2. Materials and methods
2.1. Patient selection
Patients diagnosed with AD according to the Hanifin and Rajka
criteria [26] were enrolled in Department of Dermatology, Severance
Hospital, Yonsei University Health System. AD can be categorized
into extrinsic AD, caused by entry of an external allergen, and intrin-
sic AD that occurs regardless of allergy. This can be diagnosed with
Table 1
Demographics of the subjects enrolled in the study.
AD AM HC
Total (n) 50 50 21
Male 23 26 11
Female 27 24 10
Age (Mean) 25.98 § 6.68 27.42 § 6.12 22.33 § 2.75
Age (Median, Range) 26 (2049) 27 (2045) 22 (2029)
Family history 38.89% 43.33% 
EASI score 24.52 § 9.02 26.32 § 8.77 
Total IgE 2231.73 § 1681.91 2430.75 § 1701.33 
Eosinophils (%) 6.48 § 3.91 6.81 § 4.16 
Der f (+) 82.0% 92.0% 
Abbreviations: AD, atopic dermatitis; AM, atopic march; HC, healthy control; EASI,
eczema area and severity index; Der f, Dermatophagoides farinae. Results are
expressed as mean§standard deviation.
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included [27], since intrinsic AD is not related to AM. Enrolled
patients were divided into two groups: those with AD only (AD
group) and those who also had AR and/or AA (AM group). HC were
also recruited. The diagnosis of AR and AA were confirmed by aller-
gists (authors Kyung Hee Park and Jung-Won Park) according to the
ARIA (Allergic Rhinitis and its Impact on Asthma) and GINA (Global
Initiative for Asthma) guidelines, respectively. For the sample size, as
this is an exploratory study in which the sample size calculation is
difficult, previous similar studies [28,29] were reviewed and a similar
sample size was determined. Demographics of enrolled subjects are
described in Table 1 and a study flow diagram is shown in Fig. 1.
Informed consent was obtained from all subjects, and the protocols
were approved by the Institutional Review Board of Severance Hospi-
tal (no. 420130624).
2.2. Animals
All animal procedures were approved by the Institutional Animal
Care and Use Committee of the Department of Laboratory AnimalFig. 1. Study flow diagram of atopic dermatitis (AD), atopResources, Yonsei Biomedical Research Institute, Yonsei University
College of Medicine (IACUC No. 20160007). Female NC/Nga mice (6
weeks old) were purchased from SLC Japan (Shizuoka, Japan). Mice
were kept under controlled humidity (40%) and temperature
(22 § 2 °C) conditions. HDM ointment was purchased from Biostir
Inc. (Kobe, Japan). One gram of ointment contains 234 mg of Der f 1
(a group 1 major allergen of Dermatophagoides farinae), 7 mg of Der f
2, and 134.4 mg of other proteins.
2.3. AM model development in NC/Nga mice
A total of 33 NC/Nga mice were used: 5 as HC, 12 to induce skin
lesions only (AD), and 16 to develop AM. In the first week, all NC/Nga
mice were anesthetized with 35% isoflurane using a vaporizer
(VetEquip Inc., Livermore, CA) and then their dorsum was shaved
using a razor. Hair was completely removed using hair removal
cream once per week. To disrupt the skin barrier and induce skin
inflammation, we applied 200 mL of 4% sodium dodecyl sulfate (SDS)
on the back and posterior auricular areas. After 2 h, 100 mg of HDM
ointment was applied. Epicutaneous challenges with SDS and HDM
were performed twice per week for 6 weeks (12 applications total).
To induce AM, 100mg of D. farinae antigen was delivered intranasally
daily for the last 3 d (Supplementary Fig. S1). Twenty-four hours after
the last challenge, the skin, blood, lymph nodes, spleens, and lungs
were collected to evaluate immune responses.
2.4. Microarray analysis
Total RNA in human skin biopsy samples was isolated from HC
(n = 10), AD (n = 10) and AM (n = 10) patients. Total RNA derived
from T cells was obtained from 16 patients with AD and 16 patients
with AM. All microarray analyses were performed at Macrogen
(Seoul, Korea). RNA integrity and purity were evaluated using an ND-
1000 spectrophotometer (NanoDrop, Wilmington, DE) and Agilent
2100 bioanalyzer (Agilent Technologies, Palo Alto, CA). Total RNA
was amplified and purified using a TargetAmp-Nano Labeling Kit foric march (AM) and healthy control (HC) in the study.
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tinylated cRNA according to the manufacturer’s instructions. 400 ng
of total RNA was reverse-transcribed using T7-oligo (dT) promoter
primers. Following second-strand cDNA synthesis and purification,
cRNA was quantified using an ND-1000 spectrophotometer (Nano-
Drop). Labeled cRNA was hybridized to each Human HT-12 v4.0
Expression Beadchip for 17 h at 58 °C according to the manufacturer’s
instructions (Illumina Inc., San Diego, CA). Array signal detection was
performed using Amersham fluorolink streptavidin-Cy3 (GE Health-
care Bio-Sciences, Little Chalfont, UK) following the bead array man-
ual. Arrays were scanned with an Illumina bead array reader confocal
scanner. Raw data were extracted using the manufacturer-provided
software (Illumina GenomeStudio v2011.1; Gene Expression Module
v1.9.0). All data analysis and visualization of differentially expressed
genes was performed using R 3.1.2 (www.r-project.org). Moreover,
two GEO data sets (GSE124700 (2 HC samples, 1 AD sample)
GSE124701 (1 AD sample) were utilized for pattern analyzing of gene
expression among patients’ groups. Prior to data assay, we redefined
diagnoses of atopic disease patients according to history of allergic
disease in their medical reports. Microarray data were uploaded to
the Gene Expression Omnibus (accession code GSE146352 for human
skin and GSE146356 for human T cell).2.5. Functional study using short-hairpin(sh) RNA interference2.5.1. Lentiviral plasmid vectors
MISSION pLKO.1-puro lentiviral plasmid containing mouse Fabp5,
human FABP4, FABP5 shRNA and nontargeting shRNA control were
obtained from Sigma-Aldrich. The RNAi Consortium numbers for
shRNA used in this study are TRCN0000011895 (Fabp5 for mouse),
TRCN0000059702 (FABP5 for human), TRCN0000059621 (FABP4 for
human) and SHC002 (nontargeting shRNA control). shRNA inserts
were verified using Sanger sequencing. For packing and envelop-
ment, pDVPR and pVSVG plasmids were provided by Dr. Jun-Young
Seo (Yonsei University College of Medicine).2.5.2. Lentiviral packing, production, and transduction
Murine shRNA Fabp5 or human shRNA FABP5 sequence contain-
ing and not containing recombinant lentiviruses were produced by
transient transfection of HEK293T cells plated in 100-mm dishes.
pLKO.1-Puro-shLenti (8 mg), pDVPR (8 mg), and pVSVG (8 mg) plas-
mids were co-transfected into HEK293T cells using Lipofectamine
3000 (Thermo Fisher Scientific), according to manufacturer’s instruc-
tions. The culture supernatants containing virus particles were har-
vested every 24 h post-transfection and filtered through 0.45-mm-
pore filters. HaCaT keratinocytes, human PBMCs, and murine spleno-
cytes were transduced with lentivirus through spinfection, as previ-
ously reported [30].2.6. Statistical analysis
A minimum of two independent experiments were conducted to
obtain data. Statistical analysis was conducted using SPSS version 20
(SPSS Inc., Chicago, IL, USA). Statistical differences were considered
significant at P<0.05. The correlation of nonparametric paired data
was tested using Spearman’s rho. The significance between two
groups was evaluated using unpaired t-tests and among multiple
groups was evaluated using one-way analysis of variance (ANOVA)
statistics with Tukey’s multiple comparison test or two-way ANOVA
with Dunnett’s multiple comparison test. Graphs were expressed as
mean§standard error of the mean using GraphPad Prism, version
6.01 (GraphPad Software, San Diego, CA, USA).
Additional methods are available in the Supplementary
Methods file.3. Results
3.1. AM is strongly associated with fatty acid metabolism through
FABP5 induction
First, we analyzed the clinical phenotypes of AD patients with and
without AM (Table 1). We compared the severity based on the
eczema area and severity index (EASI), serum total IgE levels, blood
eosinophil levels, and the presence of family history. Importantly,
there was no statistically significantly difference between the two
groups based on clinical characteristics. Results were similar to our
previous study [31,32].
Next, we performed whole-transcriptome analysis of HC, AD, and
AM human skin samples, which revealed differential gene expression
between the three groups (Fig. 2A). Interestingly, the genes that were
more elevated in AM patients than AD were related to fatty acid
metabolism (Fig. 2B and Supplementary Figs. S2 and S3). This sug-
gested a possible link between fatty acid metabolism and atopic
march in AD. Thus, we focused further on genes related to fatty acid-
binding proteins (FABPs) in our data sets. FABP5 and FABP5-like
(FABP5L) genes were the most highly expressed genes in the FABP
family from AM skin samples relative to AD (Fig. 2C). Consistently,
mRNA expression of FABP5, determined-by RT-PCR was statistically
significant in the AM group versus AD, but it was also significantly
different between the AD and HC groups (P = 0.0261 and P = 0.0323,
respectively, one-way ANOVA with Tukey’s multiple comparison test,
Fig. 2D).
Immunofluorescence staining further confirmed that AM patients
expressed clearly enhanced FABP5, also known as epidermal-FABP
(E-FABP), in the epidermis of AM skin compared to AD or HC skin
(Fig. 2E and F). Furthermore, BODIPY staining for intracellular lipids
revealed that AM skin had distinctly more lipid droplets than AD or
HC skin (Fig. 2G and H). These droplets were distributed not only in
the epidermis but also in the dermis (Supplementary Fig. S4), sug-
gesting an association between lipid metabolism and significant
inflammation in AM compared to AD skin.
Because survival of T cells is known to require lipid metabolism
through FABP4/5 expression [33], we compared FABP family gene
expression between AD and AM patients by using isolated T cells
(Supplementary Fig. S5). Consistent with our previous results using
skin samples, T cells from AM patients strongly expressed FABP5/
FABP5L2 genes. However, the expression of FABP4, or adipocyte-
FABP, was only slightly increased in T cells (Supplementary Fig. S5)
and in the serum of AM patients (Supplementary Fig. S6A), and it was
not increased in AM skin (Supplementary Fig. S6B). Thus, it showed
that FABP5 induction in AM skin may be related to extended inflam-
mation in fat-rich environments, like the skin, through long-term
survival of T-cells [33].
3.2. FABP5 directly upregulates Th17 in AM
To explore the type of inflammation associated with AM skin,
we further analyzed Th1/ Th2/ Th17/ Th22 inflammation-related
genes [34] in HC, AD, and AM human skin samples. This revealed
that AM was associated predominantly with increased expression
of Th17-associated genes (Fig. 3A), but Th1/ Th2/ Th22-associated
genes were not increased (Supplementary Fig. S7). Specifically,
AM skin had statistically significantly higher relative expression
of IL-17A compared to HC and AD (P = 0.0001 and P = 0.0385,
respectively, one-way ANOVA with Tukey’s multiple comparison
test, Fig. 3B).
As AM patients expressed high levels of FABP5 in both
epidermis (keratinocytes) and dermis (T cells) (Fig. 2E, F and
Supplementary Fig. S5), we performed functional studies using
shRNA interference of FABP5 in keratinocytes (HaCaT cells) and
T cells. FABP5 knockdown in HaCaT cells (Fig. 3C) resulted in
Fig. 2. Atopic march (AM) is associated with increased expression of fatty acid-binding protein 5 (FABP5). (A)Whole-transcriptome heat map of Healthy Control (HC), atopic derma-
titis (AD), and AM skin (n = 10 per group). Total RNA derived from skin biopsies was pooled 24 samples (depending on RNA amount). (B) Fatty acid metabolism-related genes upre-
gulated in AM skin. A list of genes are provided in Supplementary Table S1. (C) Bar plots displaying FABP family gene expression changes in AD and AM skin. Relative values were
normalized to HC skin. (D) Relative FABP5 expression determined by quantitative PCR (qPCR), and (E) Representative immunofluorescent FABP5 staining and (F) the intensity of
FABP5 expressions in HC, AD, and AM skin tissues (n = 5/group). (G) BODIPY staining and (H) intensity of HC, AD and AM skin (n = 3/group). Dotted line represents the epidermal-
dermal boundary. Scale bar represents 50mm. All experiments related to (D), (E) and (G)were independently performed three times.
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including IL-6 and transforming growth factor (TGF)-b (P = 0.0018
and P = 0.0031, respectively, unpaired t-test, Fig. 3D). However, this
knockdown did not significantly affect TSLP expression that enhances
Th2 response (Supplementary Fig. S8), FABP5 knockdown in humanAM T cells also significantly inhibited IL-17A expression (P < 0.0001,
unpaired t-test, Fig. 3E and F).
Furthermore, FABP5-expressing CD4+ T cells concurrently pro-
duced IL-17A and were found more abundantly in human AM skin
when compared with those from HC and AD skin (Fig. 3G and H).
Fig. 3. FABP5 enhances type 17 helper T cell (Th17) expression in AM. (A) Heat map of differentially expressed Th17 cell-related genes between human HC, AD, and AM skin (n = 10/
group). Total RNA derived from skin biopsies was pooled 24 samples (depending on RNA amount). (B) Relative IL-17A expression determined by qPCR in HC, AD, and AM skin tis-
sues (n = 5/group). (C) Confirmation of FABP5 knockdown in shFABP5-transduced human HaCaT keratinocytes. (D) Real-time PCR results of Th17-inducing cytokines (IL-6, trans-
forming growth factor [TGF]-beta) depending on FABP5 expression in HaCaT cells. (E) Confirmation of FABP5 knockdown in shFABP5-transfected T cells from AM patients. (F) Real-
time PCR results showing the effect of FABP5 knockdown on IL-17A expression in AM T cells. (G) Immunofluorescence of FABP5 and (H) percentage of FABP5+ cells in CD4- and IL-
17-producing T cells and (I and J) FABP5 expressing CD4+ CD69+ tissue-resident memory T (TRM) cells in human HC, AD, and AM skin tissues (n = 5/group). Scale bar represents
20mm. Arrowheads indicate co-stained cells. All data, except the heatmap, are representative of three independent experiments.
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Fig. 4. Overexpression of Fabp5 and Th17-related genes in AM mice. (A) Representative photographs of HC, AD, and AM mice after 6 weeks of challenge. qPCR results of (B) Fabp5,
(C) Il17a, (D) Il4, (E) Ifn-gamma, (F) Il10, and (G) Foxp3 expression in dorsal skin from HC, AD and AM mice (n = 5/group). (H) Confirmation of Fabp5 knockdown in normal murine
T cells. (I) Il17a expression in FABP5-shRNA-transduced normal murine T cells. ns, not significant; Bar graphs are representative of three independent experiments.
Table 2
Clinical characteristics of HC, AD and AMmice.





























SCORAD 0  6.200 5.3887.012 7.125 6.3267.924 0.1762
Subjective symptoms including pruritus and sleep loss were excluded from the calculation.
J. Lee et al. / EBioMedicine 58 (2020) 102879 7
8 J. Lee et al. / EBioMedicine 58 (2020) 102879These FABP5+ Th17 cells expressed CD69, indicating that they were
tissue-resident memory T (TRM) cells (Fig. 3I). TRM cells were signifi-
cantly more abundant in AM skin than HC and AD (Fig. 3J). Th17 TRM
cells were enriched in the skin of AM patients, possibly because
FABP5 directly induces Th17 polarization.3.3. Increased FABP5 and IL-17A expression in an AM murine model
To further evaluate the functional role of FABP5 in AM, we devel-
oped an AM murine model using an established AD mouse system
[35]. Specifically, NC/Nga mice received house dust mite (HDM) oint-
ment on the back and ear for six weeks and then the AM group mice
received intranasal HDM extracts for 3 days. The experimental time-
lines for each murine model are shown in supplementary Fig. S1 Rep-
resentative photographs of the mice are shown in Fig. 4A. Skin
symptom severity was assessed using SCORAD (SCORing AD) and
results are described in Table 2. Both the AD and AM murine models
had significantly higher severity than HC, but severity of AD and AM
skin did not statistically differ. AD and AM skin also had significantly
higher relative Fabp5 expression than HC (P = 0.0067 and P < 0.0001,
respectively, one-way ANOVA with Tukey’s multiple comparison
test), and AM skin expressed more Fabp5 than AD with statistical sig-
nificance (Fig. 4B). AM skin also expressed significantly higher Il-17a
than AD (P < 0.0001, one-way ANOVA with Tukey’s multiple compar-
ison test, Fig. 4C), but the two groups did not differ in terms of Il-4,
Ifn-g , Il-10, and Foxp3 expression (Fig. 4DG), which are related with
Th2 (Il-4), Th1 (Ifn-g) and regulatory T cell (Il-10, Foxp3) responses.
Finally, Fabp5 knockdown in shRNA-transduced normal murine T
cells (Fig. 4H) significantly inhibited Il-17aexpression (P < 0.0006,
unpaired t-test, Fig. 4I). Consistent with our human sample results,
these results indicated that FABP5 drives Th17 polarization in AM.3.4. FABP5 and IL-17A expression is strongly associated with lung
inflammation in AM
To investigate the functional role of FABP5 in lung tissues from
AM mice model, we assessed airway hyperresponsiveness (AHR) in
AD and AM mice using the methacholine challenge test [36]. At 25
and 50 mg/mL methacholine, AM mice demonstrated significant AHR
compared to AD (P < 0.0001, two-way ANOVA with Dunnett’s multi-
ple comparison test), clearly indicating an exaggerated AHR in AM
mice (Fig. 5A). Lungs from AM mice also expressed distinctly more
FABP5 than AD (Fig. 5B and 5C). Since FABP4 is known to be
expressed in the lung of asthma patients [37], we visualized both
FABP4 and FABP5 expression in lungs of AM mice. When visualized,
FABP5 was primarily observed in airway epithelial cells and weakly
in lung tissue, whereas FABP4 was localized to the lung tissue of AM
mice (Supplementary Fig. S9).
Next, we compared the levels of Th17 and Th2 cytokines produced
by CD4+ T cells in the skin draining lymph nodes, spleens, and lungs.
In AD and AM mice, IL-17A was significantly elevated in the lymph
nodes relative to HC (Fig. 5D). This was also increased in AMmice rel-
ative to AD, although this difference was not statistically significant.
In lung tissues, IL-17A expression was elevated in AM mice only
(Fig. 5D) with statistical significance. IL-4, a Th2 cytokine, was also
elevated in the lymph nodes of AD and AM mice, and especially high
in AM mice with statistical significance; however, IL-4 was not
increased in AM mouse lungs (Fig. 5E). This suggested that in AM
mice, IL-17A is associated with strong inflammation involving the
lungs and skin systemically. Finally, AM mice had significantly higher
serum total IgE levels than HC and AD (Fig. 5F). This indicated that
AM mice had higher HDM sensitization through both epicutaneous
and intranasal routes relative to AD mice with epicutaneous sensiti-
zation only.3.5. Dermatophagoides farinae 1 drives Th17 polarization in AM by
inducing FABP5
The only apparent clinical and laboratory difference between
AD and AM patients was increased sensitization to D. farinae and
coexistence of airway symptom (Table 1). Differences in sensitiza-
tion according to mite allergen fractions have been reported pre-
viously in patients with respiratory allergies compared to those
with AD and specifically, AD patients were mainly sensitized to
Der f 1 [38]. Therefore, we measured Der f 1-specific IgE levels in
the serum of HC, AD, and AM subjects (Fig. 6A). AD and AM
patients had significantly higher Der f 1-specific IgE levels than
HC (P < 0.0001, one-way ANOVA with Tukey’s multiple compari-
son test), and the difference between AD and AM patients was
also significant (P < 0.0001, one-way ANOVA with Tukey’s multi-
ple comparison test). As AD patients are sensitized to other mite
allergen fractions [38,39], we also evaluated IgE levels specific to
Der f 10, 11, and 14; however, these did not significantly differ
between groups (Fig. 6BD).
Next, we co-cultured dendritic cells (DCs) with CD4+ T cells and
then treated the cultures with various Der f fractions, including
whole Der f extracts (Der f), Der f 1, 2, 6, 11, and 14, to find direct evi-
dence of a relationship between allergen fraction and inflammatory
reaction in three groups. In cells from AM patients, Der f 1 treatment
significantly elevated IL-4 levels compared to cells from AD and HC
subjects (P < 0.0001, two-way ANOVA with Dunnett’s multiple com-
parison test; Fig. 6E), further supporting that AM patients are sensi-
tized to Der f 1. Der f 14 treatment also significantly increased IL-4 in
the AD and AM groups relative to HC (P < 0.0001, two-way ANOVA
with Dunnett’s multiple comparison test); however, there was no dif-
ference between AD and AM (Fig. 6E).
Finally, we assessed relative FABP5 expression in T cells from HC,
AD, and AM subjects after treatment with whole Der f extracts
(Der f), Der f 1, and Der f 14 (Fig. 6F). In these co-cultures, Der f 1 sig-
nificantly increased FABP5 expression in T cells from AM patients
compared to those from HC and AD (P < 0.0001, two-way ANOVA
with Dunnett’s multiple comparison test); however, Der f 14 treat-
ment did not significantly induce FABP5 expression (Fig. 6F). Further-
more, in T cells from AM patients, Der f 1 treatment significantly
induced IL-17A compared with those from AD (P < 0.0001, two-way
ANOVA with Dunnett’s multiple comparison test). Alternatively, Der f
14 produced lower levels of IL-17A in T cells from AM patients than
Der f 1 treatment (Fig. 6G). Overall, these results suggested that in
AM patients, Der f 1 drives Th17 polarization by inducing T cell
FABP5 expression.
3.6. FABP5 positively correlates with IL-17A
Finally, we compared serum FABP5 levels among those three
groups using enzyme-linked immunosorbent assay (ELISA). Signifi-
cant differences of serum FABP5 level were displayed not only
between HC and AD sera, but also between AD and AM (Fig. 7A).
We also used ELISA to evaluate group differences in the serum lev-
els of IL-4, IL-17A, IL-22, and IFN-g . Both AD and AM groups
expressed significantly increased IL-4 relative to HC (P = 0.0001
and P = 0.0004, respectively, one-way ANOVA with Tukey’s multi-
ple comparison test, Fig. 7B), and there was no significant differ-
ence between AD and AM groups. Both AD and AM groups
expressed significantly increased IL-17A versus HC group
(P = 0.0430 and P < 0.0001, respectively, one-way ANOVA with
Tukey’s multiple comparison test) and the difference between AD
and AM groups showed even greater statistical significance
(Fig. 7C). Similarly, both the AD and AM groups expressed statisti-
cally significantly higher IL-22compared to HC, and no differences
were observed between AD and AM (Fig. 7D). Even though
both IL-17A and IL-22 are cytokines related to Th17 response, only
Fig. 5. Increased expression of FABP5 and IL-17A in lung inflammation of AM mice. (A) Evaluation of airway hyperresponsiveness (AHR) through a methacholine challenge in HC,
AD and AM animal disease model (n = 3/group). (B) Representative confocal images showing increased FABP5 expression and (C) percentage of FABP5+ cells in the lungs of HC, AD
and AMmice (n = 3/group). Scale bar represents 50mm. Summary data of intracellular staining in (D) CD4+ IL-17a+ and (E) CD4+ IL-4+ T cells from HC, AD, and AMmice (n = 3/group).
(F) ELISA analysis of total IgE levels in HC, AD, and AM sera (n = 3/group). All experiments were independently performed three times with similar results.
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direct relationship between FABP5 and IL-17A.
Thus, we evaluated the direct correlations of serum levels of
FABP5 with each cytokine in HC, AD, and AM groups. FABP5 expres-
sion did not statistically correlate with IL-17A levels in HC and AD
groups (Fig. 7F and G) but positively correlated with IL-17A in AM
group (P = 0.041, Fig. 7H). However, FABP5 expression did not statisti-
cally correlate with IL-4, IL-22, and IFN-g levels in HC, AD, and AM
groups (Supplementary Fig. S10).4. Discussion
While several studies support that AM is a systemic disease [3,9],
the underlying pathomechanism remains unclear. Previous studies
have demonstrated that AM is associated with increased IL-17A
expression [40,41]. Systemic Th17 responses can be exacerbated by
antigen challenge through epicutaneous sensitization even in the
absence of Th2 responses, promoting airway inflammation and AHR
[41]. Our RNA microarray analysis of human skin samples revealed
A B C D
E
F G
Fig. 6. Der f 1 mediates AM progression by increasing FABP5 expression. (A-D) ELISA for (A) Der f 1, (B) Der f 10, (C) Der f 11, (D) Der f 14-specific IgEs in human HC, AD, and AM sera
(n = 6/group). (E) ELISA for IL-4 levels after co-culturing dendritic cells (DCs) and CD4+ T cells. (F, G) qPCR results of the expression of (F) FABP5 and (G) IL-17A in T cells after treating
DC/CD4+ T cell co-cultures with Der f 1, Der f 14, and whole Dermatophagoides farinae extract (Der f) (n = 6/group). ns, not significant; All figures are representative of three indepen-
dent experiments.
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IL-17 family, Th17-related cytokines. AM skin samples also demon-
strated significantly increased expression of fatty acid metabolism-
related genes. Moreover, AM patients expressed significantly pro-
nounced FABP5, the only FABP family gene that appeared highly in
AM skin samples compared to both HC and AD patients.
The skin provides a lipid-rich but nutrient-poor microenviron-
ment, and lipids are required for permeable barrier function of corni-
fied layers [42,43]. FABP5 modulates fatty acid uptake, transport, and
metabolism [44]. FABP5 is known as E-FABP because it is detected in
the granular layer of normal skin and establishes the skin barrier
function. FABP5 is also called a psoriasis-associated FABP due to its
enhanced expression in psoriatic skin, which is accompanied byhyperproliferation, impaired lipid metabolism, and abnormal differ-
entiation [45]. A relationship is established between FABP5 and AD,
as demonstrated in several studies; mass spectrometry of AD skin
showed that both acute and chronic AD lesions express significantly
more FABP5 [46]. This implies that FABP5 may play a role in AD [47].
Furthermore, extensive AM experiments comparing sputum and
nasal lavage from four groups—AR, AR+AA, non-AR, and HC—revealed
that the AR+AA group had significantly increased FABP5 expression.
This may be interpreted as evidence that FABP5 contributes to airway
remodeling and inflammation [48,49].
In our study, a heat map using whole-genome transcriptome anal-
ysis displayed increased fatty acid metabolism in AM. FABP5 and




Fig. 7. Significant positive correlation between FABP5 and IL-17A in patients with AM. (A) FABP5 expression in HC, AD, and AM sera were measured using ELISA (B-E) The expres-
sions of (B) IL-4, (C) IL-17A, (D) IL-22, and (E) IFN-g were measured in the sera of HC, AD, and AM groups by ELISA. (F-H) Correlation of IL-17A expression and FABP5 levels in the
sera of (F) HC, (G) AD, and (H) AM groups (n=21/group). ns, not significant; All experiments were independently performed three times with similar results.
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in epidermis of AM and BODIPY study revealed increased lipid
droplets in both epidermis and dermis, suggesting a role of
FABP5 in the inflammatory response and an association of lipid
metabolism in AM.
In adipose tissue, one of the main drivers of IL-17A responses is
lipid spillover [50], suggesting that the Th17 pathway is linked to
fatty acid metabolism. Interconnections between IL-17 and fat
metabolism have also been studied [51]. Since IL-17A is particularly
important in psoriasis to promote keratinocyte proliferation and
inflammation [52], strong expression of FABP5 in psoriatic epidermis
indicates a possible relationship between FABP5 and Th17 immunity
[53]. The result that Asian AD phenotype includes Th17 polarization
as well as Th2-predominant immune responses [54], also provides
evidence of Th17 involvement in AD pathogenesis. We found that
Th17-related genes and IL-17A were increased in AM skin samples.
Furthermore, FABP5 knockdown inhibited IL-6 and TGF-b expressionfrom keratinocytes and consequently, IL-17A expression from T cells.
Immunofluorescence analysis revealed that IL-17A-producing T cells
expressed FABP5, emphasizing the association between FABP5 and
IL-17A in AM skin. A previous study showed Th17 differentiation pro-
moted by FABP5 expression in CD4+ T cells [55]. It has been con-
firmed that IL-6 and TGF-b upregulate IL-17A production, and IL-6
sequentially induces IL-21 and retinoic acid-related orphan receptors
(RORs) gt and a. This ROR activation subsequently induces T cell
expression of IL-17A [56]. Taken altogether, these results emphasize
the significance of FABP5 in inducing IL-17A in AM.
FABP5 expression was more intense in TRM cells such as
CD4+CD69+ T cells of AM patients. This implies that TRM cells are not
only important in tissue-specific inflammation [57,58], but also con-
tribute to AM pathogenesis by interacting with FABP5. A recent study
showed that CD8+ TRM cells expressed significantly higher Fabp4/5,
and that Fabp4/5 deficiency reduced the long-term survival of TRM
cells [33]. We confirmed that human TRM cells from AM skin had
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these findings suggest an additional role of FABP5 in T-cell mediated
inflammation in AM patients [59].
Although our AM murine model is artificial and may not perfectly
resemble human AM, our study using Nc/Nga mice exhibited similar
results with human skin and T cells. We developed AD and AM mod-
els separately and collected samples from skin, lungs, lymph nodes,
and spleens. Just as was shown in human samples, the skin of AM
mice expressed statistically significantly increased Fabp5 and Il-17a,
a cytokine produced by Th17, compared to AD and HC. However,
cytokine levels mainly produced by other types of inflammation such
as Th2 (Il-4), Th1 (Ifn-g) and regulatory T cell (Il-10, Foxp3) did not
differ between AM and AD, implying a possible relationship between
FABP5 and Th17 inflammation, rather than Th2, Th1 and regulatory
T cell responses in AM progression.
Lung tissue from AM mice model also displayed strong FABP5
expression in airway epithelial cells and weak expression in lung tis-
sue. FABP4 was observed in lung tissue only. Past studies have shown
that FABP4 in lungs regulates the eosinophil recruitment and activa-
tion [60], and induces vascular remodeling and angiogenesis in aller-
gic asthma [37]. Our study discovered that the first inflammatory
reaction would begin when the allergen enters through the airway
with disrupted barrier, where FABP5 is strongly expressed. The
inflammatory reaction would then propagate to lung tissue where
both FABP5 and FABP4 expression was confirmed. This may explain
why serum FABP4 was also significantly increased in AM patients
showing systemic inflammation compared with HC and AD group. As
FABP4 and FABP5 are known to share genetic similarities, be present
in macrophages and regulated in an essentially identical manner
[44], we also tried to confirm whether there was any relationship
between AM progression and FABP4, in addition to FABP5. However,
in skin, FABP4 expression was increased in AD when compared with
HC but no statistical significance was found between AD and AM.
Thus, FABP4 is unlikely to be considered a possible marker to predict
AM progression due the evidence of discrepancy in the serum and
skin result.
We found that AM patients had higher sensitization to Der f 1
than AD patients. This corresponds with a recent study showing that
Der f 1 was primarily sensitized in both respiratory and cutaneous
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Fig. 8. Schematic diagram of the possible pathomechanism of atopic march (AM) and
atopic dermatitis (AD). This potential pathomechanism of AM development includes
fatty acid-binding protein 5 (FABP5) induction and predominant environments of
Th17-related cytokines following systemic sensitization through epicutaneous and
respiratory routes to a major allergen from house dust mites, e.g., Der f 1.through both epicutaneous and respiratory routes. Der f 1 also statis-
tically significantly induced FABP5 and IL-17A expression in AM,
whereas minor allergen fractions such as Der f 14 may be involved in
AD pathogenesis with cutaneous sensitization only [38].
ELISA using human serum indicated a statistically significantly
increased serum level of FABP5 in AM patients when compared with
AD and HC group. IL-4, IL-22 and IFN-g were elevated in both the AD
and AM group without significant difference between the two
groups, exhibiting similar results to mice samples. IL-17A expression
was substantially higher in the AM group, even though it was ele-
vated in both AD and AM groups. The result illustrates the constant
relationship between AM and IL-17A. A noticeable correlation
between the levels of FABP5 and IL-17A was only observed in AM
group. FABP5 expression did not correlate much with IL-4, IL-22, and
IFN-g . IL-22 is a cytokine produced by Th17, thus these results imply
FABP5 could be a potential biomarker for IL-17A expression within
Th17 inflammation in AM.
The pathomechanism of AD can be explained by Th2-skewed
immune responses that downregulate epidermal barrier protein
expression and modulate IgE class switching, ultimately enhancing
Th2 cell survival [61]. Th17 and IL-17A reportedly contribute to AD,
especially in Asian [54] and pediatric [28,62] phenotypes. In this
study, we observed that AM patients had a predominantly Th17
response through IL-17A production, which was further confirmed in
our AM murine model. A schematic pathomechanism of AM through
systemic sensitization, demonstrated in our study, is illustrated in
Fig. 8.
Our findings imply the possibility to predict the risk of AM pro-
gression with an identifiable biomarker FABP5, in relation to the past
findings regarding the mechanism of inflammation transfer within
the body system by type Th17 inflammation, mediated by IL-17A.
The importance of identifying a reliable biomarker has been strongly
addressed at the recent National Institute of Allergy and Infectious
Diseases workshop on “Atopic dermatitis and the atopic march:
Mechanisms and interventions.”[63]. So far it has been agreed that
the AM progression is highly relevant with risk factors such as AD
severity, escalated transepidermal water loss, and polysensitization
in infancy and childhood, but a prudent biomarker to indicate
patients with higher risk of AM progression in earlier stage has not
yet been identified. It is essential to predict such patients to explain
the prognosis and to provide educational support and more effective
treatment, eventually for the successful management [64]; that is
why the Institute has delivered a striking message as to the finding of
a biomarker at the workshop.
Limitations to our current study include the smaller sample
size for experiments using skin tissue compared with serum stud-
ies, as it was difficult to recruit people who are willing to
undergo skin biopsy for tissue collection. Although we have con-
firmed the direct relationship between FABP5 and IL-17 using an
experimental knockdown approach, we did not conduct overex-
pression experiments, which would provide extra confirmation.
We decided here to take a step-by-step approach and prioritize
our focus on confirming the link between FABP5 and Th17
response. This allows us to conduct future overexpression studies
in more bias-free circumstances.
In conclusion, our data strengthens the link between AM and
Th17 response by elucidating the correlation between the two
when compared with HC and AD. Also, the role of FABP5 as a
potential biomarker to predict high risk individuals for AM pro-
gression was highlighted, by confirming FABP5 overexpression
induced Th17 inflammation in AM. These findings will provide a
better understanding of the mechanism in AM progression and
give a new insight into FABP5 as a potential biomarker in AM. It
can also help clinicians and AD patients to acquire more informa-
tion about prognosis of the disease and to establish an effective
treatment plan.
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